Sirnaomics Ltd. · HKEX:2257
Sirnaomics — Investor Presentation (2022)
14 slides from Sirnaomics's investor presentation, 2022

Slide 1: Sirnaomics Ltd. Interim Data Release
Sirnaomics Ltd. [2257.HK] (Incorporated in the Cayman Islands with limited liability) Interim Data Release 0

Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by

Slide 3: Advancing Oncology Programs with the PNP Platform
Advancing Oncology Programs with the PNP Platform Delivery IND Candidate Gene Targets Indications Pre-clinical IND Phase I Phase II Phase III Rights Platform Enabling US isSCC China (MRCT)2 Global Facial isSCC US Global STP705* TGF-β1/COX-2 BCC PNP-IT US Global US Liver Cancer1 (Basket) ** China (MR

Slide 4: Sirnaomics at Value Inflection Point with Multiple Catalysts
Sirnaomics at Value Inflection Point with Multiple Catalysts Candidates 1H 2022 2H 2022 2023 Interim data isSCC readout Interim data 100% complete Final data Initiate Phase BCC readout response in Cohort 5 readout IIb trial Initiate Phase STP705 SCC IIa trial Initiate Final data Fat sculpting Phase

Slide 5: STP707 – Solid Tumor Phase I
STP707 – Solid Tumor Phase I Interim Data Discussion 4

Slide 6: Trial Design
Trial Design ◼ Multi-center open label, dose escalation and dose expansion tumor basket study to evaluate the safety, tolerability, and anti-tumor activity. 20 participants with advanced solid tumors who are refractory to standard therapy ◼ Five total cohorts who will receive escalating doses throug

Slide 7: Analysis: Based on Cohort
Analysis: Based on Cohort Patients that received >4 doses exhibit stable disease average # of days 150 ◼ Average duration stable disease from first treatment ◼ 12 mg group is ongoing at the time of analysis D u r a t io n o f R e s p o n s e ( D a y s ) 100 50 3 mg 6 mg 12 mg Mean (Days) 63.67 74.17

Slide 8: Analysis: Anatomical Location
Analysis: Anatomical Location Patients that received >4 doses average stable disease in days per tumor type 150 ◼ Average duration of stable disease in days per tumor type D u r a t io n o f R e s p o n s e ( D a y s ) 100 50 Colon Liver Pancreas Mean (Days) 70.5 89.67 75.00 0 C o lo n L iv e r P a

Slide 9: Analysis: Anatomical Location – Liver
Analysis: Anatomical Location – Liver Average number of days stable disease compared to all previous treatments; Patients that received >4 doses; All Patients showed PD with previous Tx D a ta 1 300 D u ra tio n o f R e s p o n s e (D a y s ) 200 (M e a n + /- S D ) 100 0 ST P705 STP707 5 - FL UO RO

Slide 10: Analysis: Anatomical Location – Pancreas
Analysis: Anatomical Location – Pancreas Average number of days stable disease compared to all previous treatments; Patients that received >4 doses; All Patients showed PD with previous Tx P a n c re a s 200 150 (D a y s ) D u ra tio n o f R e s p o n s e (M e a n + /- S D ) 100 50 0 STP707 ST P705

Slide 11: Analysis: Cancer Type - Melanoma
Analysis: Cancer Type - Melanoma Patients that received >4 doses; Only selected prior therapies with PD M e la n o m a A u g 2022 Oct 2022 200 0 150 (D a y s ) S c a n R e s u lt s (% d e c r e a s e ) -10 D u ra tio n o f R e s p o n s e (M e a n + /- S D ) 100 -20 50 0 -30 SSTP707 T P705 T EM O Z

Slide 12: STP705 – isSCC Phase IIb
STP705 – isSCC Phase IIb Interim Data Discussion 11

Slide 13: STP705 – isSCC Positive Phase IIb Interim Data
STP705 – isSCC Positive Phase IIb Interim Data ◼ The two-part, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy, administered as an intralesional injection in subjects with isSCC. ◼ In the part-one of the study, treated 32 patients with 30 µg/ml, 60 µg/ml and 90

Slide 14: Q&A
SITna@mics icing RNAi Therapeutic: Q&A
Source: Internet Archive copy of sirnaomics.com





